COST-EFFECTIVENESS OF A NEW FIXED-DOSE COMBINATION OF DUTASTERIDE AND TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA IN QUEBEC, CANADA

被引：0

作者：

Ismaila, A. ^{[1
]}

Posnett, J. ^{[2
]}

Walker, A. ^{[2
]}

Sayani, A. ^{[1
]}

Laroche, B. ^{[3
]}

Nickel, J. C. ^{[4
]}

Robson, R. C. ^{[1
]}

Su, Z. ^{[1
]}

机构：

[1] GlaxoSmithKline Inc, Mississauga, ON, Canada

[2] Heron Evidence Dev Ltd, Luton, Beds, England

[3] Hop St Francois Assise, Quebec City, PQ, Canada

[4] Queens Univ, Kingston, ON, Canada

来源：

VALUE IN HEALTH | 2012年 / 15卷 / 04期

关键词：

D O I：

10.1016/j.jval.2012.03.1048

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A194 / A194

页数：1

共 50 条

[21] Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia
Jameel Nazir
Lars Heemstra
Anke van Engen
Zalmai Hakimi
Cristina Ivanescu
BMC Urology, 15
[22] Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia
Nazir, Jameel
Heemstra, Lars
van Engen, Anke
Hakimi, Zalmai
Ivanescu, Cristina
BMC UROLOGY, 2015, 15
[23] Dutasteride plus Tamsulosin fixed-dose combination first-line therapy versus Tamsulosin Monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting
Geitona, Maria
Karabela, Pinelopi
Katsoulis, Ioannis A.
Kousoulakou, Hara
Lyberopoulou, Eleni
Bitros, Eleftherios
Xaplanteris, Loukas
Papanicolaou, Sotiria
BMC UROLOGY, 2014, 14
[24] Dutasteride plus Tamsulosin fixed-dose combination first-line therapy versus Tamsulosin Monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting
Maria Geitona
Pinelopi Karabela
Ioannis A Katsoulis
Hara Kousoulakou
Eleni Lyberopoulou
Eleftherios Bitros
Loukas Xaplanteris
Sotiria Papanicolaou
BMC Urology, 14
[25] Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial
Johansen, Truls E. Bjerklund
Baker, Timothy M.
Black, Libby K.
BJU INTERNATIONAL, 2012, 109 (05) : 731 - 738
[26] A combination of dutasteride, a 5α-reductase inhibitor, and tamsulosin, an alpha-adrenergic antagonist for the treatment of symptomatic benign prostatic hyperplasia
不详
FORMULARY, 2010, 45 (09) : 272 - 272
[27] A COST-UTILITY ANALYSIS OF DUTASTERIDE PLUS TAMSULOSIN COMBINATION THERAPY VERSUS TAMSULOSIN MONOTHERAPY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA IN IRAN
Peikanpour, M.
Sharif, Z.
Moghadam, Foroughi M. J.
VALUE IN HEALTH, 2017, 20 (09) : A490 - A491
[28] Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia
Dimitropoulos, Konstantinos
Gravas, Stavros
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1707 - 1716
[29] Re: Dutasteride plus Tamsulosin Fixed-Dose Combination First-Line Therapy versus Tamsulosin Monotherapy in the Treatment of Benign Prostatic Hyperplasia: A Budget Impact Analysis in the Greek Healthcare Setting Editorial Comment
Kashyap, M.
Belleville, S.
Mulsant, B. H.
Hilmer, S. Nl
Paquette, A.
Tu, L. M.
Tannenbaum, C.
JOURNAL OF UROLOGY, 2015, 194 (05): : 1354 - 1355
[30] Re: Cost-Effectiveness of Combination Therapy for Treatment of Benign Prostatic Hyperplasia: A Model Based on the Findings of the Combination of Avodart and Tamsulosin Trial Editorial Comment
Kaplan, Steven A.
JOURNAL OF UROLOGY, 2012, 188 (04): : 1237 - 1238

← 1 2 3 4 5 →